Aardvark Therapeutics, Inc. (AARD) has received a new Buy rating, initiated by JonesTrading analyst, Catherine Novack.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Catherine Novack’s rating is based on Aardvark Therapeutics’ promising clinical-stage developments and strategic positioning in the obesity treatment market. The company’s lead asset, ARD-101, is a unique oral treatment targeting Prader Willi Syndrome (PWS), a rare genetic disorder with significant unmet medical needs. The drug’s mechanism of action involves increasing the secretion of satiety hormones, potentially reducing excessive eating, which is a core symptom of PWS.
Additionally, Aardvark’s pipeline includes ARD-201, a combination treatment for general obesity, which is currently undergoing Phase 2 trials. The company’s strong cash position and upcoming data releases in 2026 are expected to be transformative, providing further validation for their therapeutic approach. The recent market performance of a competitor’s product, despite safety concerns, highlights the high demand and commercial potential for effective PWS treatments, supporting the Buy rating for Aardvark’s stock.
In another report released on September 29, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AARD in relation to earlier this year.